Abstract
Purpose
Fracture risk data following curative treatment of Cushing’s syndrome (CS) are scarce and the role of bisphosphonates in bone recovery after remission is controversial. We evaluated the effects of hypercortisolism remission in bone recovery in CS. Then, we assessed if the FRAX® algorithm calculated before the cure can predict fracture risk after cure.
Methods
Thirty-six patients with CS were retrospectively investigated. Bone turnover markers, bone mineral density (BMD) at the lumbar spine (L1–L4) and left femur (both neck and total hip were considered), and fracture risk using FRAX® algorithm with femoral neck BMD were evaluated at diagnosis and after a median follow-up of 24 months (range 12–108 months) from hypercortisolism remission. Data about bone active therapy were analyzed.
Results
Hypercortisolism remission was associated with the improvement of all densitometric parameters and with the reduction of fracture risk. The percentage change in BMD and the fracture risk were not significantly different in bisphosphonate-treated vs. untreated patients. During follow-up, three fractured patients at baseline exhibited a new vertebral fracture. A baseline 10-year probability of major osteoporotic fractures (FRAX® Major) of 17 % was able to predict the occurrence of a new vertebral fracture during follow-up after cure with 100 % sensitivity, 77 % specificity, 81 % positive predictive value and 100 % negative predictive value.
Conclusions
Osteoporosis and fracture risk may be reversible after curative treatment of CS, regardless of bisphosphonate therapy. We suggest applying the FRAX® algorithm to all active CS patients using a baseline FRAX® Major of 17 % as “intervention threshold”.
Similar content being viewed by others
References
Arnaldi G, Angeli A, Atkinson AB et al (2003) Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 88:5593–5602
Arnaldi G, Mancini T, Tirabassi G et al (2012) Advances in the epidemiology, pathogenesis, and management of Cushing’s syndrome complications. J Endocrinol Invest 35:434–448
Boscaro M, Arnaldi G (2009) Approach to the patient with possible Cushing’s syndrome. J Clin Endocrinol Metab 94:3121–3131
Valassi E, Santos A, Yaneva M et al (2011) The European Registry on Cushing’s syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol 165:383–392
Canalis E, Bilezikian JP, Angeli A et al (2004) Perspectives on glucocorticoid-induced osteoporosis. Bone 34:593–598
Van Staa TP, Laan RF, Barton IP et al (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48:3224–3229
Trementino L, Appolloni G, Ceccoli L et al (2014) Bone complications in patients with Cushing’s syndrome: looking for clinical, biochemical, and genetic determinants. Osteoporos Int 25(3):913–921
Hermus AR, Smals AG, Swinkels LM et al (1995) Bone mineral density and bone turnover before and after surgical cure of Cushing’s syndrome. J Clin Endocrinol Metab 80:2859–2865
Di Somma C, Pivonello R, Loche S et al (2003) Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing’s disease: a prospective study. Clinical Endocrinol Oxf 58:302–308
Kristo C, Jemtland R, Ueland T et al (2006) Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing’s syndrome: a prospective, long-term study. Eur J Endocrinol 154:109–118
Kawamata A, Iihara M, Okamoto T et al (2008) Bone mineral density before and after surgical cure of Cushing’s syndrome due to adrenocortical adenoma: prospective study. World J Surg 32:890–896
Randazzo ME, Grossrubatscher E, Dalino Ciaramella P et al (2012) Spontaneous recovery of bone mass after cure of endogenous hypercortisolism. Pituitary 15:193–201
Vestergaard P, Lindholm J, Jørgensen JO et al (2002) Increased risk of osteoporotic fractures in patients with Cushing’s syndrome. Eur J Endocrinol 146:51–56
Lekamwasam S, Adachi JD, Agnusdei D et al (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 23:2257–2276
Di Somma C, Colao A, Pivonello R et al (1998) Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing’s disease. Clin Endocrinol Oxf 48:655–662
Tóth M, Grossman A (2013) Glucocorticoid-induced osteoporosis: lessons from Cushing’s syndrome. Clin Endocrinol Oxf 79(1):1–11
Scillitani A, Mazziotti G, Di Somma C et al (2013) Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how? Osteoporos Int 25(2):441–446
Nieman LK, Biller BM, Findling JW et al (2008) The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93:1526–1540
Schousboe JT, Shepherd JA, Bilezikian JP, Baim S (2013) Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J Clin Densitom 16(8):455–566
Genant HK, Wu CY, Van Kuijk C et al (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137–1148
Kanis JA on behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK 2007. http://www.shef.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf
Kanis JA, Johnell O, Oden A et al (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397
World Health Organization 2007 WHO Scientific Group on the Assessment of Osteoporosis at Primary Health Care Level. Summary Meeting Report, Brussels, Belgium. www.who.int/chp/topics/rheumatic/en/index.html. Accessed 5–7 May 2004
Kanis JA, Oden A, Johnell O et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033–1046
Grossman JM, Gordon R, Ranganath VK et al (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res Hoboken 62:1515–1526
Compston J (2011) Clinical question: what is the best approach to managing glucocorticoid-induced osteoporosis? Clin Endocrinol Oxf 74:547–550
Chiodini I, Torlontano M, Carnevale V et al (2008) Skeletal involvement in adult patients with endogenous hypercortisolism. J Endocrinol Invest 31:267–276
Francucci CM, Pantanetti P, Garrapa GG et al (2002) Bone metabolism and mass in women with Cushing’s syndrome and adrenal incidentaloma. Clin Endocrinol Oxf 57:587–593
National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis 2013. http://www.nof.org/files/nof/public/content/resource/913/files/580.pdf
Kanis JA, Burlet N, Cooper C et al (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428
Papaioannou A, Morin S, Cheung AM et al (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. Can Med Assoc J 182:1864–1873
Newell-Price J, Bertagna X, Grossman AB et al (2006) Cushing’s syndrome. Lancet 367:1605–1617
Biller BM, Grossman AB, Stewart PM et al (2008) Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 93:2454–2462
Kanis JA, Johansson H, Oden A et al (2011) Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 22:809–816
Acknowledgments
The authors would like to thank Mihaela Voinea, PhD, of Excerpta Medica, who provided editorial assistance and styling prior to submission. This research was partially supported by PRIN (grant number 201098WFZ2_006).
Conflict of interest
The Authors have no conflict of interest to declare. The authors received editorial/writing support in the preparation of this manuscript provided by Excerpta Medica, funded by Novartis Oncology Region Europe. The authors did not receive honoraria related to the preparation of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Additional information
L. Trementino and L. Ceccoli contributed equally to this work.
Rights and permissions
About this article
Cite this article
Trementino, L., Ceccoli, L., Concettoni, C. et al. Fracture risk assessment before and after resolution of endogenous hypercortisolism: Is the FRAX® algorithm useful?. J Endocrinol Invest 37, 957–965 (2014). https://doi.org/10.1007/s40618-014-0126-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40618-014-0126-1